GlaxoSmithKline will reveal detailed data from clinical trials in an effort to be open and transparent about its research and drug discoveries.
Speaking at a meeting hosted by the Wellcome Trust in London, company CEO Andrew Witty will today outline its ‘open innovation’ approach to R&D, designed to enable the development of new drugs.
The move comes three months after GSK was fined $3bn after it pleaded guilty in a US court to promoting two drugs for unapproved uses and failed to report safety data about diabetes drug Avandia to the Food and Drug Administration (FDA).
The UK-based company said it would create a system where researchers can access detailed anonymised patient-level data from clinical trials. Requests for research will be reviewed by an independent panel of experts to ensure the data will be used for scientific purposes.
As part of its transparency drive, GSK has screened its pharmaceutical library for any compounds that inhibit tuberculosis bacteria and will publish the results in a scientific journal.
This is the first time a pharmaceutical company will have made public its own proprietary compounds, which have demonstrated signs of activity against TB.
Commenting ahead of the meeting, Witty said: "By being more open with our clinical trial data, we also hope to help further scientific understanding."
Wellcome Trust director Sir Mark Walport added: "Real breakthroughs do not come out of nowhere, but are borne of scientists sharing their knowledge and learning from each other. GSK’s moves are bold and innovative, a very positive sign of its commitment to tackle some of the greatest health challenges facing the world today."
Image: GSK hopes to share data to enable the discovery of new drugs. Credit: courtesy of FreeDigitalPhotos.net